 2023 is expected to be the year of new and prospective lipid-lowering therapies, LLTs, with ongoing trials, studies, and recommendations for their use in preventing cardiovascular disease, CBD, deaths. This article was authored by Macha Bonok, Stanislas Serma, and Peter P. Toth.